J&J hands over $3.1M for .Baby; Pfizer announces promising Phase III data for Lyrica;

> Johnson & Johnson ($JNJ) shelled out $3.1 million in an auction for .Baby, beating out bidders such as Google ($GOOG). Story

> Pfizer ($PFE) reported promising Phase III clinical results for its nerve-pain treatment Lyrica (pregabalin). More (sub. req.)

> The FDA's Office of Prescription Drug Promotion is cracking down on one of Sunovion's print ads for seizure med Aptiom. Story (reg. req.)

> Starting in January, the Indian government will ban pharma companies from handing out freebies to doctors. More

> Apotex submitted an application to the FDA for a copycat version of Amgen's ($AMGN) $3.5 billion blockbuster Neulasta. Story (req. req.)

And Finally… The pharma industry is funneling money into veterinary education, with the world's leading animal drugmaker, Zoetis ($ZTS), awarding $3.6 million in scholarships over the past 5 years. More

Suggested Articles

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.